• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by SciSparc Ltd

< Previous 1 2 3 4 5 Next >
News headline image
SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation For Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies
September 02, 2026
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
News headline image
SciSparc: Subsidiary NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial
August 31, 2026
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
News headline image
SciSparc Advances Agentic AI Strategy with Addition of Internationally Recognized AI Expert Prof. Carmel Domshlak to Scientific Advisory Board
August 26, 2026
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
News headline image
SciSparc: NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation
August 24, 2026
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
News headline image
SciSparc: Subsidiary NeuroThera Labs Completes C$5.4 Million Financing with SciSparc’s Stake Valued at Approximately C$30 Million
August 18, 2026
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
News headline image
SciSparc’s Subsidiary NeuroThera Labs Granted Japanese Patent for its Proprietary, Innovative Therapeutic Combination
August 12, 2026
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
News headline image
SciSparc: Subsidiary NeuroThera Labs Launches Phase IIb Clinical Trial at Yale Child Study Center for First-of-its-kind Treatment for Tourette Syndrome
August 05, 2026
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
News headline image
SciSparc: Subsidiary NeuroThera Labs' Quantum Platform Demonstrates Complete End-to-End Hybrid Quantum-Classical Workflow for Clinical Data Analytics
July 31, 2026
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
News headline image
SciSparc: Subsidiary NeuroThera Labs Advances its Quantum Platform for Clinical Data Analytics on a Platform of an S&P 500 company
July 29, 2026
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC TSX-V:NTLX
News headline image
SciSparc Announces Decision to Target the Agentic AI Market; Forms Scientific Advisory Board for Artificial Intelligence and Cybersecurity
July 27, 2026
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
News headline image
SciSparc: NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndrome
July 15, 2026
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC TSX-V:NTLX
News headline image
SciSparc: Subsidiary NeuroThera Labs Completed Acquisition of CliniQuantum
June 04, 2026
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
News headline image
SciSparc: Subsidiary NeuroThera Labs Received Conditional Regulatory Approval for Acquisition of CliniQuantum
May 28, 2026
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
News headline image
SciSparc: NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy
March 16, 2026
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
News headline image
SciSparc: NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease
March 12, 2026
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
News headline image
SciSparc: Subsidiary NeuroThera Labs (75%) Signs Definitive Agreement to Acquire Majority Stake in CliniQuantum, Innovator in Quantum-based Clinical trails
March 10, 2026
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
News headline image
SciSparc Announces 1-for-9 Reverse Share Split
March 02, 2026
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
News headline image
SciSparc: NeuroThera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance such as MRSA
February 02, 2026
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
News headline image
SciSparc Successfully Completes Acquisition of IP Portfolio, Advances Toward Immediate Commercialization
January 26, 2026
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
News headline image
SciSparc Signs Definitive Agreement to Acquire a Treasury of Patents for the Endoscope Market- Entering Multi-Billion Dollar Opportunity
January 13, 2026
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
News headline image
SciSparc Announces Receipt of Nasdaq Notification of Minimum Stockholders’ Equity Non-Compliance
January 12, 2026
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
News headline image
SciSparc: Neurothera Labs Granted Patent by Israeli Patent Office for its Proprietary Opioid-Based Patent Family to Enhance Pain Relief and Reduce Side Effects
December 30, 2025
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
News headline image
SciSparc: Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis Company
December 02, 2025
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
News headline image
SciSparc Plans on Entering the Multi-Billion-Dollar GERD Device Market with Acquisition of an Approved IP Portfolio
December 01, 2025
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
News headline image
SciSparc to Acquire Treasury of Patents for Innovative Medical Endoscopy Systems
November 26, 2025
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
News headline image
SciSparc: Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression
November 20, 2025
From SciSparc Ltd
Via GlobeNewswire
Tickers CMND SPRC TSX-V:NTLX
News headline image
SciSparc Announces Closing of the Acquisition of a Publicly Traded Company on the TSXV to which it transferred its Advanced Clinical Stage Pharmaceutical Portfolio
October 24, 2025
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
News headline image
SciSparc Announces Closing of the Sale to N2OFF of Majority-Owned Subsidiary MitoCareX, Advancing Drug Discovery for Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer
October 23, 2025
From SciSparc Ltd
Via GlobeNewswire
Tickers NITO SPRC
News headline image
SciSparc Targets Quantum-Powered 3D Protein Modeling Technology to Revolutionize AI Drug Discovery
October 23, 2025
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
News headline image
SciSparc-Clearmind Collaboration Leads to Publication of U.S. Patent Application Targeting Binge Behavior Disorders
October 20, 2025
From SciSparc Ltd
Via GlobeNewswire
Tickers CMND SPRC
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap